# Preemptive Lung Impedance-Guided Therapy in Evolving Acute Heart Failure in Acute Myocardial Infarction Patients

> **NCT01616121** · PHASE3 · COMPLETED · sponsor: **Hillel Yaffe Medical Center** · enrollment: 654 (actual)

## Conditions studied

- Heart Failure

## Interventions

- **OTHER:** Usual treatment of patients with developing acute heart failure
- **DEVICE:** Lung Impedance-Guided Therapy

## Key facts

- **NCT ID:** NCT01616121
- **Lead sponsor:** Hillel Yaffe Medical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-06-01
- **Primary completion:** 2014-07-01
- **Final completion:** 2014-07-01
- **Target enrollment:** 654 (ACTUAL)
- **Last updated:** 2020-06-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01616121

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01616121, "Preemptive Lung Impedance-Guided Therapy in Evolving Acute Heart Failure in Acute Myocardial Infarction Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01616121. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*